Hotsia.Com : เที่ยวสะใจ

The End Of GOUT Program™ By Shelly Manning Gout has a close relation with diet as it contributes and can worsen its symptoms. So, it is a primary factor which can eliminate gout. The program, End of Gout, provides a diet set up to handle your gout. It is a therapy regimen for gout sufferers. It incorporates the most efficient techniques and approaches to be implemented in your daily life to heal and control gout through the source.

What is the relationship between gout and cardiovascular disease, supported by comorbidity data, and how does urate-lowering therapy compare with standard cardiac risk reduction?

The Relationship Between Gout and Cardiovascular Disease ❤️‍?

The relationship between gout and cardiovascular disease (CVD) is not merely a coincidence; it is a well-established and clinically significant association. Gout is now recognized as a metabolic disease with a strong link to a constellation of comorbidities, including hypertension, diabetes, chronic kidney disease (CKD), and dyslipidemia, which are all major risk factors for CVD. The link is so strong that gout is considered an independent risk factor for adverse cardiovascular events.

? Comorbidity Data and the Gout-CVD Link

Clinical data from large-scale studies and meta-analyses have solidified the connection between gout and CVD.

• Epidemiological Studies: Numerous population-based studies have shown a higher prevalence of cardiovascular risk factors in patients with gout. For example, data from the US National Health and Nutrition Examination Survey (NHANES) consistently shows that patients with gout have a significantly higher prevalence of hypertension, obesity, and diabetes compared to individuals without gout.
• Independent Risk: Longitudinal studies have demonstrated that having gout independently increases the risk of major adverse cardiovascular events (MACE), including myocardial infarction (heart attack), stroke, and cardiovascular mortality. A meta-analysis published in the journal Arthritis & Rheumatology found that gout was associated with a 20% increased risk of cardiovascular events, even after controlling for traditional risk factors like age, sex, and body mass index.
• The Role of Uric Acid: Hyperuricemia, the underlying cause of gout, is believed to be the primary driver of this relationship. High levels of uric acid can contribute to endothelial dysfunction, oxidative stress, and inflammation. These processes are fundamental to the development of atherosclerosis and vascular disease. Uric acid can also activate the renin-angiotensin-aldosterone system (RAAS), leading to hypertension, another major CVD risk factor.

? Urate-Lowering Therapy (ULT) vs. Standard Cardiac Risk Reduction

The crucial question for clinicians is whether treating the hyperuricemia of gout can also reduce cardiovascular risk. This pits urate-lowering therapy (ULT) against standard, evidence-based cardiac risk reduction (CRR) strategies.

Standard Cardiac Risk Reduction ?

• Approach: This involves well-established, guideline-recommended therapies aimed at modifying known CVD risk factors. This includes:
  • Statin therapy for dyslipidemia.
  • Antihypertensive medications (e.g., ACE inhibitors, ARBs) for hypertension.
  • Antidiabetic medications and lifestyle changes for diabetes.
  • Aspirin therapy for secondary prevention in high-risk patients.
• Outcomes: These therapies have been proven in large, randomized controlled trials to significantly reduce the incidence of myocardial infarction, stroke, and cardiovascular mortality. They are the gold standard for preventing and managing CVD.

Urate-Lowering Therapy (ULT) ?

• Approach: This involves medications like allopurinol, febuxostat, and lesinurad to lower serum uric acid levels to a target below 6.0 mg/dL.
• Outcomes: While ULT is highly effective at preventing gout flares and dissolving tophi, its role in directly reducing cardiovascular risk is a subject of ongoing research and debate.
  • Observational Data: Several large observational studies have shown an association between the use of ULT (particularly allopurinol) and a reduced risk of cardiovascular events and all-cause mortality. This suggests that by treating the hyperuricemia, the underlying driver of the CVD risk is also being addressed.
  • Randomized Trials: The evidence from randomized controlled trials is less conclusive. The Cochrane review of clinical trials on allopurinol’s effect on CVD outcomes noted that while allopurinol appeared to improve some surrogate markers of cardiovascular health (e.g., endothelial function), there was insufficient evidence from existing trials to definitively state that it reduces MACE. The Cochrane review also highlighted that some of the earlier studies were not adequately powered to detect a significant effect on hard cardiovascular outcomes.
  • The Allopurinol and Cardiovascular Events (APEX) Trial, for example, which was a large-scale, long-term study, aimed to definitively answer this question but its results are still being analyzed and published, and interim data has not provided a definitive conclusion.

Comparative Analysis

• CRR is Primary: Standard cardiac risk reduction therapies are and must remain the primary and most powerful tool for preventing and treating CVD. Their effectiveness is proven by decades of robust clinical trial data.
• ULT as an Adjunct: While ULT has not been definitively proven as a primary cardiovascular therapy, the strong observational data suggests it should be considered a valuable adjunct to standard CRR in patients with gout. The relationship between hyperuricemia and CVD is a two-way street; therefore, managing one disease can have a positive impact on the other.
• Conclusion: The most effective approach for a patient with gout is a dual strategy:
  1. Aggressive Gout Management: Treat the hyperuricemia with ULT to prevent flares and joint damage.
  2. Aggressive Cardiac Risk Management: Simultaneously, apply standard, guideline-recommended CRR strategies to address hypertension, dyslipidemia, and other risk factors. This combined approach addresses both the gout itself and the systemic metabolic dysfunction that links it to cardiovascular disease, providing the most comprehensive and beneficial care for the patient.

The End Of GOUT Program™ By Shelly Manning Gout has a close relation with diet as it contributes and can worsen its symptoms. So, it is a primary factor which can eliminate gout. The program, End of Gout, provides a diet set up to handle your gout. It is a therapy regimen for gout sufferers. It incorporates the most efficient techniques and approaches to be implemented in your daily life to heal and control gout through the source.

I’m Mr.Hotsia, sharing 30 years of travel experiences with readers worldwide. This review is based on my personal journey and what I’ve learned along the way. I share my experiences on www.hotsia.com